Back to discover
Disease

Embolic Stroke

Late-stage therapeutic developmentEmerging research
MeSHEmbolic Stroke
2
Publications
24
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 3 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
Clinical Milestones8View
Results expected 3
Recently completed 2
Other updates 3
Activity timeline8

Clinical trials

14 sponsors · 2 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
14
Late-stage
6
Completed
Late-stage studies

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Patients With Acute Ischemic Strokes With Large Infarct: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial (MIRACLE)

Phase 3 · Active, not recruiting · Wan-Jin Chen

Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)

Phase 4 · Active, not recruiting · Seoul National University Hospital

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-2 (IRIS-2)

Phase 3 · Active, not recruiting · Capital Medical University

Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Phase 3 · Completed · H. Lundbeck A/S

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)

Phase 3 · Completed · Boehringer Ingelheim
Recently completed

Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Phase 3 · Completed · H. Lundbeck A/S

Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon Carotid Intima-media Complex Thickness in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)

Phase 3 · Completed · Boehringer Ingelheim

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily

Phase 3 · Completed · Boehringer Ingelheim

EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study

Phase 4 · Completed · Boehringer Ingelheim

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2020–2024
Major themes1
  • Embolic Stroke1
Leading journals2
  • European heart journal1
  • International journal of molecular sciences1
Leading researchers8
  • Baumgartner H1
  • Daidone M1
  • Doehner W1
  • Donal E1
  • Edvardsen T1
  • Healey JS1
  • Iung B1
  • Kamel H1
Affiliations (unnormalised)6
  • Azienda Ospedaliero Universitaria (A.O.U.)1
  • Bichat Hospital1
  • Center of Stroke Research Berlin1
  • Clinical and Translational Neuroscience Unit1
  • Danish Center for Health Services Research1
  • Department of Clinical Therapeutics1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An ischemic stroke due to a blood clot, emboli or other types of blockage which forms somewhere other than the brain and subsequently travels near and restricts blood flow to the brain. Most often the origin of the clot is from the heart and is referred to as cardioembolic stroke.

Identifiers
MeSHEmbolic Stroke
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.